| 貨號(hào) | 規(guī)格 | 價(jià)格 | 上海 | 北京 | 武漢 | 南京 | 購(gòu)買(mǎi)數(shù)量 |
|---|---|---|---|---|---|---|---|
S20616-1mg |
≥98% | ￥240.00 | 貨期：2-3天 | - | - | - |
|
S20616-5mg |
≥98% | ￥350.00 | 貨期：2-3天 | - | - | - |
|
S20616-10mg |
≥98% | ￥465.00 | 貨期：2-3天 | - | - | - |
|
S20616-25mg |
≥98% | ￥720.00 | 貨期：2-3天 | - | - | - |
|
S20616-50mg |
≥98% | ￥1370.00 | 貨期：2-3天 | - | - | - |
|
S20616-100mg |
≥98% | ￥2700.00 | 貨期：2-3天 | - | - | - |
|
S20616-1g |
≥98% | ￥21000.00 | 貨期：2-3天 | - | - | - |
|
GSK-3β inhibitor 2 (Compound 3) 是一種有效，選擇性和口服活性的 GSK-3β 抑制劑，IC50 為 1.1 nM。GSK-3β inhibitor 2 可以穿越血腦屏障。GSK-3β inhibitor 2 有用于阿爾茨海默氏病的潛力。
| 產(chǎn)品描述： | GSK-3β inhibitor 2 (Compound 3) 是一種有效，選擇性和口服活性的 GSK-3β 抑制劑，IC50 為 1.1 nM。GSK-3β inhibitor 2 可以穿越血腦屏障。GSK-3β inhibitor 2 有用于阿爾茨海默氏病的潛力。 |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點(diǎn)： | GSK-3β 1.1 nM (IC50);GSK-3 | ||||||||||||||||||||
| 體外研究： | The pyridine carboxamide of GSK-3β inhibitor 2 (Compound 3) makes hydrogen bonds with the hinge V135 backbone amide, and the carbonyl oxygen of the thiazolyl primary amide formed a critical hydrogen bond with K85. The quality of the electron density for the methyl group of the methoxy moiety in GSK-3β inhibitor 2 does not allow its unambiguous placement in the model, but a small molecule crystal structure of GSK-3β inhibitor 2 determined by single crystal X-ray diffraction method confirmed the intramolecular hydrogen bonding between the methoxy -O- and the amide N-H in GSK-3β inhibitor 2. | ||||||||||||||||||||
| 體內(nèi)研究： | The elevation of hyperphosphorylated Tau (pTau) is mimicked in LaFerla 3xTg-C57BL6 mice, and accordingly, these mice are used as an in vivo model of Alzheimer’s disease. GSK-3β inhibitor 2 (Compound 3) shows a significant reduction in pTau396 when administered orally at 30 mg/kg as a nanosuspension to LaFerla 3xTg-C57BL6 male mice. GSK-3β inhibitor 2 shows only modest brain exposure (B/P = 0.26) as determined as a single time point. | ||||||||||||||||||||
| 參考文獻(xiàn)： | 1.Sivaprakasam P, et al. Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core. Bioorg Med Chem Lett. 2015 May 1;25(9):1856-63. | ||||||||||||||||||||
| 保存條件： | -20°C | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶(hù)參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號(hào)
危險(xiǎn)品化學(xué)品經(jīng)營(yíng)許可證（不帶存儲(chǔ)）
營(yíng)業(yè)執(zhí)照(三證合一)
掃一掃關(guān)注上海源葉微信公眾號(hào)
北京